Stock Events

BioInvent International AB 

SEK36.4
0
+SEK0+0% Thursday 14:53

Statistics

Day High
36.4
Day Low
36.4
52W High
48.58
52W Low
26.35
Volume
1,492
Avg. Volume
30
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26OctConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-1.71
-0.19
1.34
2.86
Expected EPS
-1.17
Actual EPS
-1

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0H22.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Roche
RHHBY
Mkt Cap191.27B
Roche Holding AG is a major player in biotechnology and pharmaceuticals, focusing on oncology, immunology, and targeted therapies, directly competing with BioInvent's focus areas.
AMGEN
AMGN
Mkt Cap166.77B
Amgen Inc. specializes in biotechnological research and development, particularly in treatments involving antibodies, similar to BioInvent's antibody-based therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap111.64B
Regeneron Pharmaceuticals, Inc. is known for its innovative biologic medicines, including those in oncology and immunology, overlapping with BioInvent's research domains.
Gilead Sciences
GILD
Mkt Cap83.09B
Gilead Sciences, Inc. competes in the biopharmaceutical field, focusing on serious diseases like cancer, which is a key area for BioInvent.
Bristol-Myers Squibb
BMY
Mkt Cap80.39B
Bristol-Myers Squibb Company operates extensively in biopharmaceuticals, particularly in cancer and immune disorders, competing with BioInvent's therapeutic areas.
Novartis
NVS
Mkt Cap236.8B
Novartis AG engages in extensive research in healthcare and biotechnology, including therapies for cancer and immune disorders, areas where BioInvent is also active.
Merck &
MRK
Mkt Cap320.27B
Merck & Co., Inc. is a global healthcare company that develops treatments for cancer and immune-mediated diseases, directly competing with BioInvent.
Pfizer
PFE
Mkt Cap158.95B
Pfizer Inc. is involved in biopharmaceuticals, focusing on immunology and oncology, which are central to BioInvent's business.
Lilly(Eli) &
LLY
Mkt Cap869.21B
Eli Lilly and Company focuses on pharmaceuticals, including cancer and immunology, competing in the same therapeutic areas as BioInvent.
Astrazeneca
AZN
Mkt Cap239.79B
AstraZeneca PLC specializes in the discovery and development of drugs for major disease areas including cancer, directly competing with BioInvent's oncology focus.

About

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
Show more...
CEO
Dr. Martin Welschof Ph.D.
Employees
109
Country
SE
ISIN
SE0015244520
WKN
000A2QJRW

Listings